RemeGen Co

RemeGen Co Retained Earnings

The Retained Earnings of RemeGen Co (688331.SS) as of Oct 26, 2026 is -3.61 B CNY. In the previous year, Retained Earnings was -4.32 B CNY — a change of -16.55% (higher).

Retained Earnings

-3.61 BCNY

YoY

-16.55%

Last updated:

Retained Earnings of RemeGen Co is 2025 -3.61 B CNY. Retained Earnings of RemeGen Co was 2024 -4.32 B CNY. It decreases by -16.55% higher compared to the previous year.

The RemeGen Co Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-572.81 M CNY
Jan 1, 2019
-1.00 B CNY
Jan 1, 2020
-619.71 M CNY
Jan 1, 2021
-343.45 M CNY
Jan 1, 2022
-1.34 B CNY
Jan 1, 2023
-2.85 B CNY
Jan 1, 2024
-4.32 B CNY
Jan 1, 2025
-3.61 B CNY
The RemeGen Co Retained Earnings history
YEARRetained EarningsYoY
-3.61 BCNY-16.55%
-4.32 BCNY+51.46%
-2.85 BCNY+112.59%
-1.34 BCNY+290.82%
-343.45 MCNY-44.58%
-619.71 MCNY-38.22%
-1.00 BCNY+75.12%
-572.81 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Retained Earnings of RemeGen Co is -3.61 B CNY in 2025.

Retained Earnings of RemeGen Co changed from -4.32 B CNY to -3.61 B CNY, representing a -16.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RemeGen Co

All Key Metrics — RemeGen Co